panitumumab
- Generic Name
- panitumumab
- Brand Names
- Vectibix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 339177-26-3
- Unique Ingredient Identifier
- 6A901E312A
- Background
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Panitumumab was granted FDA approval on 27 September 2006.
- Indication
美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。
- Associated Conditions
- Metastatic Colorectal Cancer (CRC)
- Associated Therapies
- -
Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 180
- Registration Number
- NCT02904031
- Locations
- 🇮🇹
Istituto Oncologico Veneto IRCCS, Padua, Italy
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 348
- Registration Number
- NCT02885753
- Locations
- 🇫🇷
Hôpital André Mignot, Le Chesnay, France
🇫🇷Hôpital Belle Isle, Metz, France
🇫🇷CHR, Orleans, France
Carboplatin and Paclitaxel with or Without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT02876107
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations
- Conditions
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 133
- Registration Number
- NCT02818725
- Locations
- 🇫🇷
Chu de Nimes, Nimes, France
🇫🇷Institut Paoli Calmettes, Marseille, France
🇫🇷Hopital Saint Andre, Bordeaux, France
Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Southern Europe New Drug Organization
- Target Recruit Count
- 32
- Registration Number
- NCT02643056
Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2016-09-14
- Target Recruit Count
- 224
- Registration Number
- NCT02476045
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei tumori, Milano, MI, Italy
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 14
- Registration Number
- NCT02399943
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 58
- Registration Number
- NCT02301962
- Locations
- 🇮🇳
DRL Investigational Site, New Delhi, India
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3091
- Registration Number
- NCT02089737
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT01927341
- Locations
- 🇺🇸
University of California at Los Angeles Dept of Onc, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center Oncology Dept, New York, New York, United States
🇪🇸Pfizer Investigative Site, Barcelona, Catalunya, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.